Tamtam Try Tamtam free
Neurocrine Biosciences logo

Neurocrine Biosciences account plan

Developing treatments for disorders

At a glance

Neurocrine Biosciences is a San Diego neuroscience biopharma company with $2,860.5 million FY2025 revenue and about 2,000 employees.

Neurocrine Biosciences is a San Diego neuroscience-focused biopharmaceutical company that discovers, develops and sells treatments for neurological, psychiatric, endocrine and immunological disorders, primarily in the U.S. Its marketed medicines are INGREZZA (tardive dyskinesia and Huntington's chorea), CRENESSITY (classic congenital adrenal hyperplasia) and, since the May 2026 Soleno Therapeutics acquisition, VYKAT XR for hyperphagia in Prader-Willi syndrome. FY2025 total revenues were $2,860.5 million (2024: $2,355.3 million), with net income of $478.6 million and about 2,000 full-time employees at year-end. It relies on third-party manufacturers and reports a single segment.

Business units

Strategic priorities

Grow the three commercial medicines
Maximize INGREZZA, CRENESSITY and VYKAT XR; the sales force of approximately 600 was expanded in Q1 2026, and full-year 2026 INGREZZA guidance was raised to $2,900-2,925 million.
Phase 3 readouts in 2027
Initial Phase 3 topline data for osavampator in major depressive disorder and direclidine in schizophrenia are expected in 2027, with a second direclidine Phase 3 in 2028.
Steady flow of new medicines
The company aims to launch about one new medicine every two years and to advance at least four new programs into Phase 1 and two into Phase 2 each year; 2026 brought 6 Phase I and 5 new Phase II starts.
Obesity and immunology expansion
NBIP-2118 (CRF2 agonist) and NBIP-1968 (GLP-1/GIP/glucagon triple agonist) are in Phase 1 to inform a co-formulated combination, and NBIM-'1008 started Phase 1 for rheumatoid arthritis.
Move into biologics and gene therapy
R&D is being transformed to include peptides, proteins, antibodies, conjugates and gene therapies, with substantial investment in personnel and facilities.

Latest results

In Q3 2026 (three months to September 30, 2026) total revenues were $1,122.7 million, up from $794.9 million, and net product sales exceeded $1 billion for the first time. INGREZZA grew 17% to $801 million (including a $20 million order-timing benefit expected to reverse in Q4), CRENESSITY rose 115% to $211 million and VYKAT XR added $107 million. GAAP net income was $206.5 million ($1.96 per share) against $209.5 million, weighed by a $52.3 million unrealized loss on equity investments; non-GAAP net income was $347 million. Full-year 2026 INGREZZA guidance was raised to $2,900-2,925 million and GAAP SG&A guidance lowered to $1,540-1,560 million, with GAAP R&D unchanged at $1,275-1,325 million.

Investments and deals

Soleno Therapeutics acquisition
All-cash acquisition closed May 18, 2026, with a total equity value of approximately $2.9 billion, adding VYKAT XR; product rights valued at $2.2 billion are amortized over 16 years.
Revolving credit facility
A five-year $1.0 billion senior secured revolving credit facility signed in May 2026; $600.0 million was borrowed in May and repaid in June.
In-licensing partnerships
Deals with Nxera (direclidine), Takeda (osavampator), Xenon and Voyager; potential future milestone payments under collaborations rose to up to $16.5 billion.
Share repurchases
1.1 million shares were repurchased for $158.1 million in the first nine months of 2026, with $174.2 million remaining under the 2025 program.
Divestment of Neurocrine Group Limited
Sold to Immedica Pharma AB on January 21, 2026 for $63.2 million in cash.

Challenges and risks

Dependence on INGREZZA
INGREZZA was about 88% of FY2025 revenues and faces Teva's AUSTEDO, whose lower Medicare negotiated price "may increase competitive pressures on INGREZZA".
Drug pricing pressure
INGREZZA's Medicare negotiated price applies from 2029, and the CFO expects mid- to high single-digit net pricing headwinds in 2027.
Legal and regulatory scrutiny
A DOJ civil investigative demand on INGREZZA sales and marketing was received in August 2025, alongside patent challenges such as Zydus's ANDA on INGREZZA SPRINKLE.
Clinical risk
In 2025 Phase 3 studies of valbenazine in schizophrenia and in dyskinesia due to cerebral palsy missed their primary endpoints, and VYKAT XR growth may be delayed after safety reports in the media.
Reliance on third-party manufacturing
Neurocrine has no manufacturing of its own and depends on a limited number of third-party suppliers, while expanding into biologics and device-based therapies.

What leadership says

“another important milestone in Neurocrine's evolution, with net product sales exceeding $1 billion for the first time, driven by strong underlying demand across our diversified portfolio of first-in-class medicines”

Kyle W. Gano, Chief Executive Officer · Third-quarter 2026 financial results release, November 2, 2026

“Never in Neurocrine's 35-year history, we have achieved this level of R&D productivity in a single year.”

Kyle W. Gano, Chief Executive Officer · Q3 2026 earnings call, November 2, 2026

“Just a few years ago, we were largely viewed as a single product company.”

Kyle W. Gano, Chief Executive Officer · Q2 2026 earnings call, July 30, 2026

“driving commercial growth, advancing high-value pipeline programs and pursuing disciplined business development”

Matthew C. Abernethy, Chief Financial Officer · Capital allocation priorities, Q3 2026 earnings call, November 2, 2026

Where a supplier can help

Contract manufacturing and supply
With no in-house manufacturing and a move into biologics (challenge: reliance on third-party manufacturing; priority: move into biologics), CDMOs, peptide and biologics manufacturers and supply chain partners fit.
Clinical trial services
Phase 3 programs for osavampator and direclidine plus many new Phase 1 and Phase 2 starts (priority: Phase 3 readouts in 2027) call for CRO, site, patient recruitment and data services.
Commercial and field sales tools
The expanded sales force and possible primary-care launch (priority: grow the three commercial medicines) need CRM, field analytics, HCP engagement and patient services support.
Compliance and market access
The DOJ inquiry and Medicare pricing pressure (challenges: legal and regulatory scrutiny, drug pricing pressure) make compliance monitoring, pricing analytics and payer-contracting tools relevant.
Integration support
Integrating Soleno and VYKAT XR (investment: Soleno Therapeutics acquisition) opens room for integration, rare-disease patient support and pharmacovigilance services.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like Neurocrine Biosciences?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about Neurocrine Biosciences

What does Neurocrine Biosciences do?

It is a San Diego neuroscience-focused biopharmaceutical company selling INGREZZA, CRENESSITY and VYKAT XR, and developing treatments in psychiatry, neurology, endocrinology, obesity and immunology.

What is Neurocrine Biosciences' revenue?

FY2025 total revenues were $2,860.5 million (2024: $2,355.3 million). In Q3 2026 total revenues reached $1,122.7 million.

How many employees does Neurocrine Biosciences have?

About 2,000 full-time employees as of December 31, 2025, primarily in the U.S.

Who leads Neurocrine Biosciences?

Kyle W. Gano is Chief Executive Officer, Matthew C. Abernethy is Chief Financial Officer and William H. Rastetter chairs the Board.

What is Neurocrine Biosciences' strategy?

Grow its three marketed medicines, deliver Phase 3 readouts for osavampator and direclidine in 2027, launch about one new medicine every two years and diversify into obesity, immunology and biologics.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)